We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes
Previous Study | Return to List | Next Study

Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04843527
Recruitment Status : Recruiting
First Posted : April 13, 2021
Last Update Posted : November 18, 2022
Sponsor:
Information provided by (Responsible Party):
Abbott Diabetes Care

Brief Summary:
A multi-center, randomized, prospective, non-significant risk study to compare the impact of the FreeStyle Libre Flash Glucose Monitoring System with and without a food logging smartphone application on reducing time above 180 mg/dL in subjects with type 2 diabetes who are not adequately controlled on their existing oral anti-diabetes medication regimen.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Device: FreeStyle Libre System Device: FreeStyle Libre System plus food app Not Applicable

Detailed Description:

Approximately 350 subjects will be enrolled to obtain at least 84 randomized subjects,approximately 42 subjects per arm. Subjects will be randomized to use either the FreeStyle Libre Flash Glucose Monitoring System or FreeStyle Libre Flash Glucose Monitoring System with a food logging smartphone application to manage their diabetes.

The subsequent impact on reducing the amount of time spent above 180 mg/dL will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People
Actual Study Start Date : April 2, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hyperglycemia

Arm Intervention/treatment
Active Comparator: FreeStyle Libre
Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.
Device: FreeStyle Libre System
FreeStyle Libre Flash Glucose Monitoring System

Active Comparator: FreeStyle Libre plus food logging
Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.
Device: FreeStyle Libre System plus food app
FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application




Primary Outcome Measures :
  1. Impact on time above 180 mg/dL [ Time Frame: Three (3) months ]
    To assess the impact of the FreeStyle Libre Flash Glucose Monitoring System with and with food logging app on time above 180 mg/dL



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be at least 18 years of age.
  • Subject has been diagnosed with type 2 diabetes.
  • HbA1c greater than or equal to 7.5% and less than or equal to 12%
  • Subject is on at least 1 diabetes medication in the classes of metformin, SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors.
  • Subject owns a compatible smartphone
  • Subject agrees to a 3-month period of no diabetes medication changes.
  • Subject is willing to make diet and lifestyle changes in response to education and glucose data

Exclusion Criteria:

  • Subject is currently on insulin therapy or sulfonylurea-based medications.
  • Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
  • Subject is known to be pregnant at the time of study enrollment (applicable to female subjects only).
  • Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04843527


Locations
Layout table for location information
United States, Massachusetts
Boston Medical Center Recruiting
Boston, Massachusetts, United States, 02118
Contact: Devin SteenKamp, MD    617-638-7470    desteenk@bu.edu   
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Davida Kruger    313-916-3906    dkruger1@hfhs.org   
United States, Minnesota
HealthPartners Institute dba International Diabetes Center Recruiting
Minneapolis, Minnesota, United States, 55416
Contact: Thomas Martens, MD    952-993-4865    Thomas.martens@parknicollet.com   
United States, Pennsylvania
UMPC Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Esra Karslioglu French, MD    412-586-9700    karslioglufrenche@upmc.edu   
Sponsors and Collaborators
Abbott Diabetes Care
Investigators
Layout table for investigator information
Study Director: Shridhara A Karinka, PhD Abbott Diabetes Care Inc
Layout table for additonal information
Responsible Party: Abbott Diabetes Care
ClinicalTrials.gov Identifier: NCT04843527    
Other Study ID Numbers: ADC-US-RES-19185
First Posted: April 13, 2021    Key Record Dates
Last Update Posted: November 18, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Hyperglycemia
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases